Search results for "MESH: Humans"

showing 10 items of 211 documents

Determinants of interest in extended-released buprenorphine: A survey among 366 French patients treated with buprenorphine or methadone

2021

International audience; Aim: To explore the factors determining the interest in extended-release buprenorphine (XR-BUP) injections among patients receiving opioid agonist treatment (OAT) in France.Methods: 366 patients receiving OAT for opioid use disorder, recruited in 66 French centers, were interviewed from 12/2018 to 05/2019. A structured questionnaire assessed their interest in XR-BUP using a [1-10] Likert scale. 'More' vs. 'less' interested groups were defined using the median score of interest, and their characteristics were explored using adjusted odds ratios (aORs) and 95 % confidence interval (95 %CI). Independent variables were as follows: sociodemographic characteristics, OAT-re…

MaleNarcotic Antagonists[SDV]Life Sciences [q-bio]ToxicologyMESH: Analgesics Opioid0302 clinical medicineInterquartile rangeSurveys and QuestionnairesPharmacology (medical)030212 general & internal medicineSurveymedia_commonMESH: Patient PreferenceMESH: Middle AgedOpioid use disorderPatient PreferenceMiddle AgedBuprenorphineAnalgesics OpioidPsychiatry and Mental healthMESH: Young AdultFemaleFranceMESH: Narcotic AntagonistsPatients' preferencemedicine.drugAdultmedicine.medical_specialtyAdolescentMESH: Delayed-Action Preparationsmedia_common.quotation_subjectMESH: BuprenorphineMESH: Opiate Substitution TreatmentInjections03 medical and health sciencesYoung AdultInternal medicinemedicineOpiate Substitution TreatmentHumansMESH: InjectionsDosingMESH: Surveys and QuestionnairesPharmacologyMESH: AdolescentMESH: Humansbusiness.industryMESH: AdultOdds ratioAbstinencemedicine.diseaseOpioid-Related DisordersConfidence intervalMESH: MaleMESH: Opioid-Related DisordersMESH: FranceDelayed-Action PreparationsMESH: MethadoneExtended-releasebusinessMESH: Female030217 neurology & neurosurgeryMethadoneMethadoneBuprenorphine
researchProduct

Occupational solvent exposure and risk of glioma in the INTEROCC study

2017

BACKGROUND: The aetiology of glioma remains largely unknown. Occupational solvent exposure has been suggested as a putative cause of glioma, but past studies have been inconsistent. We examined the association between a range of solvents and glioma risk within the INTEROCC project, a study of brain tumours and occupational exposures based on data from seven national case-control studies conducted in the framework of the INTERPHONE study. We also investigated associations according to tumour grade.METHODS: Data from the seven countries were standardised and then combined into one aggregate data set. Pooled odds ratios (ORs) were estimated for adjusted models that included sex, age, country-r…

MaleOncologyMESH: United KingdomCancer ResearchEpidemiology[SDV]Life Sciences [q-bio]MESH: Neoplasm GradingMESH: SolventsMESH: Occupational ExposureMESH: GliomaTumor gradechemistry.chemical_compound0302 clinical medicineRisk FactorsMESH: New ZealandMESH: Risk FactorsGermanyOdds RatioIsraelYoung adultMESH: AgedOccupationMESH: Middle AgedBrain NeoplasmsAge FactorsMESH: IsraelGliomaMiddle Aged030210 environmental & occupational healthMESH: Case-Control Studies3. Good healthOncologyMESH: Young Adult030220 oncology & carcinogenesisSolventMESH: Brain NeoplasmsFemaleFranceAdultCanadamedicine.medical_specialtyAdolescentCase–control studyJob-exposure matrixMESH: AustraliaYoung Adult03 medical and health sciencesSex FactorsMESH: Sex FactorsMESH: CanadaOccupational ExposureInternal medicineGliomamedicineJournal ArticleHumansMESH: GermanyAgedMESH: AdolescentMESH: Age FactorsMESH: Humansbusiness.industryAustraliaCase-control studyMESH: AdultOdds ratiomedicine.diseaseUnited KingdomConfidence intervalMESH: MaleMESH: Odds RatioMESH: FrancechemistryCase-Control StudiesSolventsNeoplasm GradingSolvent exposurebusinessMESH: FemaleNew Zealand
researchProduct

Impact of recommendations on the initial therapy of Parkinson’s disease: A population-based study in France

2011

International audience; Levodopa induces long-term motor complications in Parkinson's disease (PD). Therapeutic strategies that prevent motor complications are needed. Our aim was to evaluate the impact of recommendations of a French consensus conference published in 2000 on initial PD therapy. We identified 308 PD patients as part of a population-based study performed within the Mutualité Sociale Agricole in five French districts (2007). Neurologists confirmed PD diagnosis. We compared initial therapy in 102 patients treated before 12/31/2000 to that of 206 patients treated afterwards. Initial treatment was in agreement with the recommendations if dopamine agonists were used in patients <6…

MaleParkinson's diseaseEpidemiologyConsensus Development Conferences as TopicParkinson's diseaseMESH: Antiparkinson AgentsDiseaseAntiparkinson AgentsLevodopa0302 clinical medicineMESH: Practice Guidelines as TopicEpidemiology030212 general & internal medicinePractice Patterns Physicians'Initial therapyMESH: Dopamine AgonistsMESH: AgedMESH: Levodopaeducation.field_of_studyMESH: Middle AgedConsensus conferenceParkinson DiseaseMiddle Aged3. Good healthNeurologyDopamine AgonistsPractice Guidelines as TopicMESH: Guideline AdherenceFemaleFranceGuideline Adherencemedicine.drugmedicine.medical_specialtyLevodopaPopulationGuidelines03 medical and health sciencesInternal medicineMedical practicemedicineHumansMESH: Physician's Practice PatternseducationAgedMESH: HumansMESH: Consensus Development Conferences as Topicbusiness.industrymedicine.diseaseMESH: MaleMESH: FrancePopulation based study[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologiePhysical therapy[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologieNeurology (clinical)Geriatrics and GerontologybusinessMESH: FemaleMESH: Parkinson Disease030217 neurology & neurosurgeryParkinsonism &amp; Related Disorders
researchProduct

Th1 and Th17 lymphocytes expressing CD161 are implicated in giant cell arteritis and polymyalgia rheumatica pathogenesis.

2012

International audience; OBJECTIVE: Giant cell arteritis (GCA) is the most frequently occurring vasculitis in elderly individuals, and its pathogenesis is not fully understood. The objective of this study was to decipher the role of the major CD4+ T cell subsets in GCA and its rheumatologic form, polymyalgia rheumatica (PMR). METHODS: A prospective study of the phenotype and the function of major CD4+ T cell subsets (Th1, Th17, and Treg cells) was performed in 34 untreated patients with GCA or PMR, in comparison with 31 healthy control subjects and with the 27 treated patients who remained after the 7 others withdrew. RESULTS: Compared with control subjects, patients with GCA and patients wi…

MalePathologyMESH: Th17 CellsCellMESH : AgedMESH : Prospective StudiesMESH: Flow CytometryT-Lymphocytes RegulatoryPathogenesisMESH : T-Lymphocytes Regulatory0302 clinical medicineimmune system diseasesMESH : Th1 CellsImmunology and Allergy[ SDV.IMM ] Life Sciences [q-bio]/ImmunologyPharmacology (medical)MESH : FemaleProspective Studiesskin and connective tissue diseasesCells CulturedMESH: Aged0303 health sciencesMESH: Middle Agedmedicine.diagnostic_testMESH: Giant Cell ArteritisCell DifferentiationMESH : AdultMiddle AgedFlow CytometryMESH : NK Cell Lectin-Like Receptor Subfamily B3. Good healthMESH: NK Cell Lectin-Like Receptor Subfamily Bmedicine.anatomical_structure[SDV.IMM]Life Sciences [q-bio]/ImmunologyFemaleVasculitisMESH : Cell DifferentiationGlucocorticoidmedicine.drugNK Cell Lectin-Like Receptor Subfamily BMESH: Cells CulturedAdultMESH: Cell Differentiationmedicine.medical_specialty[SDV.IMM] Life Sciences [q-bio]/ImmunologyMESH : Flow CytometryT cellMESH : MaleImmunologyGiant Cell ArteritisBiologyPolymyalgia rheumatica03 medical and health sciencesRheumatologyBiopsyMESH : Cells CulturedmedicineMESH : Th17 CellsHumansMESH : Middle Aged030304 developmental biologyAged030203 arthritis & rheumatologyMESH: HumansMESH: T-Lymphocytes RegulatoryMESH : HumansMESH: AdultTh1 Cellsmedicine.diseaseMESH : Giant Cell ArteritisMESH: Prospective StudiesMESH: MaleGiant cell arteritisMESH: Th1 CellsPolymyalgia RheumaticaMESH: Polymyalgia RheumaticaImmunologyTh17 CellsMESH : Polymyalgia RheumaticaMESH: Female
researchProduct

Generalised sensory system abnormalities in amyotrophic lateral sclerosis: a European multicentre study.

2007

International audience; BACKGROUND: Amyotrophic lateral sclerosis (ALS) is defined as a disease of the motor neurones, although several studies indicate involvement of the sensory nervous system. AIM: To evaluate the sensory nerve conduction studies (NCS) in 88 patients with ALS as part of a European multicentre study. METHODS: Seven European clinical neurophysiologists examined consecutive series of ALS patients. The examinations were peer reviewed, and the diagnosis of ALS was confirmed clinically. RESULTS: 20 (22.7%) patients with ALS had sensory NCS abnormalities in at least one nerve. Of those, 11 (12.5% of all patients) obtained an additional peer review diagnosis of electrophysiologi…

MalePathologyNeural Conduction0302 clinical medicineMESH: Aged 80 and overDorsal root ganglionMESH: Neural ConductionAmyotrophic lateral sclerosisMESH: Amyotrophic Lateral SclerosisAged 80 and overMESH: Aged0303 health sciencesMESH: ElectrophysiologyMESH: Middle AgedMESH: Neurons AfferentMiddle AgedElectrophysiologyEuropePsychiatry and Mental healthmedicine.anatomical_structureMESH: Sensation DisordersSensation DisordersFemale[SDV.NEU]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]PolyneuropathySensory nerveAdultmedicine.medical_specialtyNeuromuscular diseaseShort ReportSensory systemCentral nervous system disease03 medical and health sciencesmedicineHumans[SDV.NEU] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]Neurons AfferentAged030304 developmental biologyMESH: Humansbusiness.industryAmyotrophic Lateral SclerosisMESH: Adultmedicine.diseaseMESH: MaleSurgeryNeurology (clinical)MESH: EuropebusinessMotor neurone diseaseMESH: Female030217 neurology & neurosurgery
researchProduct

Growth hormone potentiates thyroid hormone effects on post-exercise phosphocreatine recovery in skeletal muscle.

2012

International audience; OBJECTIVE: The aim of the study was to determine the respective impact of thyroxine and growth hormone on in vivo skeletal mitochondrial function assessed via post exercise phosphocreatine recovery. DESIGN: The hind leg muscles of 32 hypophysectomized rats were investigated using (31)P nuclear magnetic resonance spectroscopy at rest and during the recovery period following a non tetanic stimulation of the sciatic nerve. Each rat was supplemented with hydrocortisone and was randomly assigned to one of the 4 groups: the group Hx was maintained in hypopituitarism., the group HxT was treated with 1 μg/100g/day of thyroxine (T4), the group HxG with 0.2 IU/kg/day of recomb…

MalePhosphocreatineThyroid hormonesEndocrinology Diabetes and MetabolismMESH: Random AllocationThyroid GlandSkeletal muscleHypopituitarismMESH: Physical Conditioning AnimalMESH: Drug SynergismNuclear magnetic resonancechemistry.chemical_compoundRandom Allocation0302 clinical medicineEndocrinologyMESH: Human Growth HormoneMESH: AnimalsMESH : Muscle Skeletal0303 health sciencesMESH: Muscle Skeletal[ INFO.INFO-IM ] Computer Science [cs]/Medical ImagingMESH : RatsHuman Growth HormoneThyroidDrug Synergismmedicine.anatomical_structuremedicine.drugmedicine.medical_specialtyMESH : Drug SynergismMESH: RatsMESH : MaleSomatotropin030209 endocrinology & metabolismMESH: PhosphocreatinePhosphocreatineMESH : Random Allocation03 medical and health sciencesIn vivoInternal medicine[ SDV.MHEP ] Life Sciences [q-bio]/Human health and pathologyPhysical Conditioning AnimalMESH : Thyroxinemedicine[INFO.INFO-IM]Computer Science [cs]/Medical ImagingAnimalsHumansMESH : PhosphocreatineMESH : Human Growth HormoneMitochondrionMESH : Physical Conditioning AnimalMuscle Skeletal030304 developmental biologyHydrocortisoneMESH: HumansMESH : HumansSkeletal muscleMESH : Thyroid GlandMESH: Thyroxinemedicine.diseaseMESH: MaleMESH: Thyroid GlandRatsThyroxineEndocrinologychemistryRatMESH : AnimalsTetanic stimulation[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyHormoneGrowth hormoneIGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society
researchProduct

Vorapaxar in the secondary prevention of atherothrombotic events

2012

BACKGROUND: Thrombin potently activates platelets through the protease-activated receptor PAR-1. Vorapaxar is a novel antiplatelet agent that selectively inhibits the cellular actions of thrombin through antagonism of PAR-1. METHODS: We randomly assigned 26,449 patients who had a history of myocardial infarction, ischemic stroke, or peripheral arterial disease to receive vorapaxar (2.5 mg daily) or matching placebo and followed them for a median of 30 months. The primary efficacy end point was the composite of death from cardiovascular causes, myocardial infarction, or stroke. After 2 years, the data and safety monitoring board recommended discontinuation of the study treatment in patients …

MalePyridines[SDV]Life Sciences [q-bio]Myocardial InfarctionMedizinKaplan-Meier Estimate030204 cardiovascular system & hematologyBrain IschemiaLactones0302 clinical medicineMESH: Peripheral Arterial DiseaseSecondary PreventionMESH: Double-Blind Method030212 general & internal medicineMyocardial infarctionStrokeVorapaxarMESH: AgedAspirinMESH: Middle AgedMESH: RiskCardiovascular diseases [NCEBP 14]MESH: Secondary PreventionHazard ratioMESH: Brain IschemiaGeneral MedicineMiddle AgedClopidogrel3. Good healthStrokeMESH: Receptor PAR-1MESH: Myocardial Infarctionvorapaxar secondary prevention atherothrombotic eventsCardiovascular DiseasesMESH: Platelet Aggregation InhibitorsAnesthesiaRetreatmentPlatelet aggregation inhibitorFemaleIntracranial HemorrhagesMESH: HemorrhageMESH: Intracranial HemorrhagesMESH: Lactonescirculatory and respiratory physiologymedicine.drugRiskISQUEMIA CEREBRALHemorrhagePlaceboMESH: StrokePeripheral Arterial Disease03 medical and health sciencesDouble-Blind Method[INFO.INFO-IM]Computer Science [cs]/Medical ImagingmedicineHumansReceptor PAR-1MESH: RetreatmentMESH: Kaplan-Meier EstimateAgedMESH: Humansbusiness.industryMESH: PyridinesMESH: Cardiovascular Diseasesmedicine.diseaseSettore MED/11 - Malattie Dell'Apparato CardiovascolareMESH: MalebusinessMESH: FemalePlatelet Aggregation Inhibitors
researchProduct

Normal Reference Ranges for Echocardiography: Rationale, study design, and methodology (NORRE Study)

2013

International audience; BACKGROUND: Availability of normative reference values for cardiac chamber dimensions, volumes, mass, and function is a prerequisite for the accurate application of echocardiography for both clinical and research purposes. However, due to the lack of consistency in current echocardiographic 'reference values', their use for clinical decision-making remains questionable. AIMS: The aim of the 'Normal Reference Ranges for Echocardiography Study (NORRE Study)' is to obtain a set of 'normal values' for cardiac chamber geometry and function in a large cohort of healthy Caucasian individuals aged over a wide range of ages (25-75 years) using both conventional and advanced e…

MaleRadiology Nuclear Medicine and ImagingMESH: Echocardiography DopplerLeftSex Factor030204 cardiovascular system & hematologyDoppler echocardiographyDoppler imagingMESH: Stroke VolumeMESH: Ventricular Function LeftVentricular Function Left030218 nuclear medicine & medical imagingHeart VentricleCohort Studies0302 clinical medicine[INFO.INFO-TS]Computer Science [cs]/Signal and Image ProcessingNuclear Medicine and ImagingVentricular FunctionAge FactorProspective StudiesProspective cohort studyMESH: Cohort StudiesMESH: Aged2D and 3D echocardiographyMESH: Middle Agedmedicine.diagnostic_testAnthropometryAge FactorsDopplerGeneral MedicinePulsedReference Standardsreference valuesMiddle AgedCardiac mechanicEchocardiography Doppler3. Good healthEuropeMESH: Echocardiography Doppler PulsedCardiac mechanicsEchocardiographyMESH: Reference Standards[SDV.IB]Life Sciences [q-bio]/BioengineeringFemaleRadiologyCardiology and Cardiovascular Medicine[SPI.SIGNAL]Engineering Sciences [physics]/Signal and Image processingCohort study2D and 3D echocardiography; Cardiac mechanics; Chamber size and function; M-mode; reference values; Adult; Age Factors; Aged; Anthropometry; Cohort Studies; Echocardiography Doppler; Echocardiography Doppler Pulsed; Europe; Female; Heart Ventricles; Humans; Male; Middle Aged; Prospective Studies; Reference Standards; Sensitivity and Specificity; Sex Factors; Stroke Volume; Ventricular Function Left; Cardiology and Cardiovascular Medicine; Radiology Nuclear Medicine and ImagingHumanAdultmedicine.medical_specialtyHeart VentriclesM-modeChamber size and functionSensitivity and Specificity03 medical and health sciencesSex FactorsMESH: Sex FactorsMESH: Anthropometry[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemmedicineHumansMedical physicsAgedMESH: Age FactorsEchocardiography Doppler PulsedReproducibilityMESH: Humansbusiness.industryreference valueMESH: AdultStroke VolumeMESH: MaleMESH: Prospective StudiesMESH: Sensitivity and SpecificitySurgeryClinical trialProspective StudieSample size determinationReference StandardObservational studyMESH: EuropeMESH: Heart VentriclesCohort StudiebusinessMESH: Female
researchProduct

The role of taste in food acceptance at the beginning of complementary feeding

2011

article présenté lors du 18. Annual Meeting of the Society-for-the-Study-of-Ingestive-Behavior ; Pittsburgh, Pennsylvanie (Etats-Unis) - (2010-07-13 - 2010-07-17) / Rencontres; International audience; Introduction of solid foods is a major step in the establishment of eating behavior and is likely to affect children's health. However, the role of taste in acceptance of new foods, in particular in the first months of complementary feeding, is not fully understood and was the aim of the present study. Infants had to be in good health to participate (N=74). First, the infants' reactions to new foods were recorded by their parents between the ages of 5 and 7 months using a 4-point-scale ranging…

MaleTasteMESH: Infant Nutritional Physiological PhenomenaMESH : Infant Nutritional Physiological Phenomena[ SDV.AEN ] Life Sciences [q-bio]/Food and NutritionUmamiMESH : TasteMESH: EatingFood groupEatingBehavioral NeuroscienceIngredientMedicineIngestionMESH : FemaleFood scienceInfant Nutritional Physiological PhenomenaMESH : Food Preferencesdigestive oral and skin physiologyMESH : InfantMESH : Feeding BehaviorMESH: InfantnutritionTasteMESH: Feeding BehaviorEating behaviorFemaleMESH : EatingMESH : Malefood acceptanceExperimental and Cognitive PsychologyWeaningAffect (psychology)complementary feedingFood PreferencesMESH: WeaningHumansMESH: Food PreferencesMESH: Humansbehaviorbusiness.industryMESH : HumansInfantFood acceptanceFeeding BehaviorMESH : WeaningMESH: Maletaste preferenceMESH: TastebusinessMESH: Female[SDV.AEN]Life Sciences [q-bio]/Food and NutritionPhysiology &amp; Behavior
researchProduct

Increased Activity of Coagulation Factor XII (Hageman Factor) Causes Hereditary Angioedema Type III

2006

International audience; Hereditary angioedema (HAE) is characterized clinically by recurrent acute skin swelling, abdominal pain, and potentially life-threatening laryngeal edema. Three forms of HAE have been described. The classic forms, HAE types I and II, occur as a consequence of mutations in the C1-inhibitor gene. In contrast to HAE types I and II, HAE type III has been observed exclusively in women, where it appears to be correlated with conditions of high estrogen levels--for example, pregnancy or the use of oral contraceptives. A recent report proposed two missense mutations (c.1032C-->A and c.1032C-->G) in F12, the gene encoding human coagulation factor XII (FXII, or Hageman factor…

MaleTime FactorsKinins030204 cardiovascular system & hematologyMESH: Founder Effect[SDV.IMM.II]Life Sciences [q-bio]/Immunology/Innate immunityLinkage Disequilibrium0302 clinical medicineMissense mutationHereditary Angioedema Type IIIGenetics(clinical)MESH: Models GeneticGenetics (clinical)MESH: Heterozygote0303 health sciencesFactor XII[SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/HematologyFounder EffectMarkov ChainsPedigree3. Good healthMESH: Linkage DisequilibriumFactor XIIHereditary angioedemaFemalemedicine.symptomMESH: Factor XIIHeterozygotemedicine.medical_specialtyMESH: MutationMESH: PedigreeMESH: Bayes TheoremCoagulation Factor XIIBiology03 medical and health sciencesMESH: Markov ChainsReportInternal medicinemedicineGeneticsHumansMESH: AngioedemaAngioedema030304 developmental biologyMESH: HumansModels GeneticAngioedemaHaplotypeMESH: Time FactorsBayes TheoremHeterozygote advantageMESH: Haplotypesmedicine.diseaseMESH: KininsMESH: MaleEndocrinologyHaplotypesMutationImmunologyMESH: Microsatellite RepeatsMESH: FemaleMicrosatellite RepeatsThe American Journal of Human Genetics
researchProduct